Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic … Read more
Navidea Biopharmaceuticals Inc (NAVB) - Total Liabilities
Latest total liabilities as of September 2023: $8.68 Million USD
Based on the latest financial reports, Navidea Biopharmaceuticals Inc (NAVB) has total liabilities worth $8.68 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Navidea Biopharmaceuticals Inc - Total Liabilities Trend (1992–2022)
This chart illustrates how Navidea Biopharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Navidea Biopharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Navidea Biopharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
808 Renewable Energy Corp
PINK:RNWR
|
USA | $2.70 Million |
|
Olimpo Real Estate SA
MC:YORE
|
Spain | €167.52 Million |
|
ilShinbiobase Co. Ltd
KO:068330
|
Korea | ₩2.66 Billion |
Liability Composition Analysis (1992–2022)
This chart breaks down Navidea Biopharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Navidea Biopharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Navidea Biopharmaceuticals Inc (1992–2022)
The table below shows the annual total liabilities of Navidea Biopharmaceuticals Inc from 1992 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $12.51 Million | +107.89% |
| 2021-12-31 | $6.02 Million | +5.41% |
| 2020-12-31 | $5.71 Million | +13.50% |
| 2019-12-31 | $5.03 Million | +9.13% |
| 2018-12-31 | $4.61 Million | -47.20% |
| 2017-12-31 | $8.73 Million | -89.10% |
| 2016-12-31 | $80.13 Million | +16.46% |
| 2015-12-31 | $68.80 Million | +64.90% |
| 2014-12-31 | $41.72 Million | -5.87% |
| 2013-12-31 | $44.33 Million | +231.34% |
| 2012-12-31 | $13.38 Million | +32.95% |
| 2011-12-31 | $10.06 Million | +49.49% |
| 2010-12-31 | $6.73 Million | -64.36% |
| 2009-12-31 | $18.89 Million | +95.82% |
| 2008-12-31 | $9.65 Million | -12.37% |
| 2007-12-31 | $11.01 Million | +32.11% |
| 2006-12-31 | $8.33 Million | +10.30% |
| 2005-12-31 | $7.55 Million | -17.91% |
| 2004-12-31 | $9.20 Million | +332.81% |
| 2003-12-31 | $2.13 Million | -31.85% |
| 2002-12-31 | $3.12 Million | -29.50% |
| 2001-12-31 | $4.43 Million | -3.95% |
| 2000-12-31 | $4.61 Million | -55.96% |
| 1999-12-31 | $10.46 Million | +45.94% |
| 1998-12-31 | $7.17 Million | -20.52% |
| 1997-12-31 | $9.02 Million | +4.92% |
| 1996-12-31 | $8.60 Million | +109.66% |
| 1995-12-31 | $4.10 Million | 0.00% |
| 1994-12-31 | $4.10 Million | +127.78% |
| 1993-12-31 | $1.80 Million | +200.00% |
| 1992-12-31 | $600.00K | -- |